A

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Senior Manager/Associate Director Medical Affairs & Scientific Engagement

Biology & BiotechConfirmed live in the last 24 hours
Full-timeChesterbrook, PA, USANo salary listed

About the Job

Requirements

  • An advanced scientific or clinical degree in a relevant discipline, such as an MD, DO, DNP, NP, or PA in Dermatology or Rheumatology.
  • At least 5 years of relevant experience in clinical dermatology practice, rheumatology, biotechnology, pharmaceuticals, Medical Affairs, Clinical Development, or related scientific roles.
  • Experience in Medical Affairs, field medical or Medical Science Liaison work, clinical trial liaison work, or as a clinician in dermatology or rheumatology.
  • Ability to interpret and communicate complex scientific and clinical data to internal and external audiences.
  • Experience building relationships with key opinion leaders, investigators, healthcare professionals, or academic researchers.
  • Organizational and project-management skills, including the ability to manage multiple priorities and work independently across functional boundaries.
  • Written, verbal, presentation, and interpersonal communication skills.
  • Ability to travel approximately 30–50% based on field, study, and congress needs.

Responsibilities

  • Support development and execution of the Medical Affairs strategy and annual medical plan aligned with clinical development and organizational objectives.
  • Develop and execute scientific communication strategies covering emerging clinical data, disease-state information, mechanism of action, treatment landscape, and unmet medical need.
  • Build peer-to-peer scientific relationships with key opinion leaders, investigators, healthcare professionals, academic institutions, and external experts in hidradenitis suppurativa, dermatology, and immune-mediated inflammatory diseases.
  • Conduct non-promotional scientific exchange regarding hidradenitis suppurativa disease biology, treatment landscape, mechanism of action, emerging scientific evidence, and company-sponsored clinical programs.
  • Develop and support medical education initiatives on hidradenitis suppurativa, the patient journey, treatment patterns, unmet medical needs, and emerging scientific evidence.
  • Develop scientific slide decks, disease-state materials, frequently asked questions, field medical resources, investigator materials, training programs, and other scientific communication tools.
  • Capture insights from external experts and clinical study sites and translate them into recommendations for Medical Affairs and Clinical Development.
  • Support development and execution of an integrated publication strategy and plan aligned with clinical development milestones and Medical Affairs objectives.
  • Partner with Clinical Development, Biostatistics, Medical Writing, and external authors to identify publication opportunities from clinical trials, scientific analyses, and evidence-generation activities.
  • Coordinate abstracts, posters, oral presentations, manuscripts, encore presentations, and other scientific communications.
  • Manage publication timelines, authorship coordination, internal review, external vendors, and congress submission deadlines.
  • Identify appropriate opportunities to communicate emerging scientific and clinical evidence through peer-reviewed publications and scientific forums.
  • Ensure publication activities are scientifically rigorous, appropriately reviewed, and consistent with publication standards and company policies.
  • Support development and execution of medical congress strategy for major dermatology, immunology, and relevant scientific meetings.
  • Identify priority congresses based on scientific relevance, clinical development milestones, data-readout opportunities, key opinion leader participation, and Medical Affairs objectives.
  • Develop congress scientific objectives, coverage plans, key opinion leader engagement strategies, scientific communication plans, and internal briefing materials.
  • Coordinate abstracts, posters, presentations, scientific sessions, advisory boards, investigator meetings, and other Medical Affairs activities surrounding major congresses.
  • Provide scientific support at congresses and conferences, including key opinion leader meetings, scientific exchange, poster and presentation support, competitive intelligence, and internal education.
  • Monitor relevant scientific presentations and competitive clinical data and provide post-congress summaries of implications for clinical development and Medical Affairs strategy.
  • Facilitate post-congress education and disseminate key scientific learnings to appropriate internal stakeholders.
  • Develop disease-state and scientific education programs for healthcare professionals, investigators, study-site personnel, and other appropriate external stakeholders.
  • Educate external stakeholders on hidradenitis suppurativa biology, disease burden, patient journey, current treatment approaches, unmet medical needs, emerging science, and relevant clinical research.
  • Support advisory boards and other external expert engagements, including scientific objectives, participant identification, materials preparation, meeting facilitation, and synthesis of insights.
  • Partner with internal and external experts to develop scientifically accurate educational resources on disease state and evolving clinical evidence.
  • Respond to unsolicited medical and scientific inquiries through established Medical Affairs processes.
  • Serve as a scientific liaison among Avalo, clinical investigators, study coordinators, research staff, Clinical Development, Clinical Operations, and Medical Affairs.
  • Provide disease-state and scientific education to investigators and clinical study sites on hidradenitis suppurativa, the patient journey, disease severity, treatment patterns, and the scientific rationale for the clinical development program.
  • Educate study sites on the intended clinical trial patient profile, including disease characteristics, severity, previous treatments, patient journey, inclusion and exclusion criteria, and other protocol-defined characteristics relevant to identifying potentially appropriate patients.
  • Help investigators and study personnel understand where potentially eligible patients may be found in their clinical practices, referral networks, and broader dermatology community.
  • Provide scientific education and resources supporting patient identification, screening, recruitment, enrollment, and retention, while maintaining separation between Medical Affairs activities and site-management responsibilities.
  • Partner with Clinical Development and Clinical Operations to understand recruitment and enrollment barriers, including patient availability, referral patterns, competing trials, screen failures, protocol complexity, disease recognition, and patient burden.
  • Gather feedback from investigators and clinical study sites about patient profiles, eligibility criteria, screening challenges, recruitment barriers, treatment patterns, and protocol feasibility.
  • Translate site and investigator insights into actionable recommendations for Clinical Development, Clinical Operations, and Medical Affairs.
  • Support investigator meetings, site-engagement meetings, scientific training, site initiation activities, and other study-related educational programs as appropriate.
  • Help develop investigator-facing disease-state education, patient-profile materials, scientific frequently asked questions, study-awareness materials, and recruitment-support resources through established review and approval processes.
  • Support relationships between clinical study sites and appropriate referring healthcare professionals through scientifically appropriate disease and study education.
  • Review enrollment and screening trends with Clinical Development and Clinical Operations to identify sites or geographic areas where additional scientific education or patient-profile awareness may support enrollment.
  • Maintain awareness of the competitive clinical trial landscape and communicate implications for investigator engagement, patient availability, recruitment, and enrollment.
  • Collaborate with Medical Affairs, Clinical Development, Clinical Operations, Regulatory Affairs, Pharmacovigilance, Biometrics, Translational Medicine, HEOR/Market Access, and Commercial colleagues as appropriate.
  • Translate emerging clinical data into scientific communication, publication, congress, and medical education strategies.
  • Systematically capture and communicate insights from key opinion leaders, investigators, study sites, congresses, and scientific literature to appropriate internal stakeholders.
  • Maintain current knowledge of hidradenitis suppurativa biology, treatment guidelines, patient journeys, referral pathways, clinical literature, competitive development programs, and emerging scientific developments.
  • Represent Avalo with scientific credibility and professionalism at medical congresses, scientific meetings, investigator meetings, advisory boards, and other external forums.
  • Ensure activities comply with applicable legal, regulatory, compliance, good clinical practice, patient privacy, and company requirements.

Desired Qualifications

  • Demonstrated experience supporting publication planning, scientific communications, medical congresses, medical education, advisory boards, or related Medical Affairs activities.
  • Membership in a dermatology organization, such as AAD, AOCD, DEF, SDPA, or DNPA.

About the Company

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Avalo Therapeutics develops biologic therapies that target the IL-1beta pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody that inhibits IL-1beta and blocks downstream inflammatory signaling, advancing toward a registrational Phase 3 program after positive Phase 2 results in hidradenitis suppurativa. AVTX-010 is a long-acting next-generation anti-IL-1beta antibody designed to extend dosing intervals. The company focuses on research and development of novel biologics with commercialization expected through pharmaceutical partnerships and product sales. Unlike some competitors that pursue broader or different inflammatory targets, Avalo concentrates specifically on IL-1beta–related inflammation with a pipeline aimed at improving dosing convenience and clinical outcomes in inflammatory diseases.

Company size
51-200
Company stage
IPO
Headquarters
Rockville, MD
Founded
2011

Recently Posted Jobs

Explore more opportunities at Avalo Therapeutics

See more jobs